A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.

indirect comparisons network meta-analysis nonproportional hazards time-to-event outcomes

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
04 2023
Historique:
received: 09 05 2022
revised: 17 11 2022
accepted: 24 11 2022
medline: 4 4 2023
pubmed: 13 12 2022
entrez: 12 12 2022
Statut: ppublish

Résumé

Network meta-analysis (NMA) of time-to-event outcomes based on constant hazard ratios can result in biased findings when the proportional hazards (PHs) assumption does not hold in a subset of trials. We aimed to summarize the published non-PH NMA methods for time-to-event outcomes, demonstrate their application, and compare their results. The following non-PH NMA methods were compared through an illustrative case study in oncology of 4 randomized controlled trials in terms of progression-free survival and overall survival: (1) 1-step or (2) 2-step multivariate NMAs based on traditional survival distributions or fractional polynomials, (3) NMAs with restricted cubic splines for baseline hazard, and (4) restricted mean survival NMA. For progression-free survival, the PH assumption did not hold across trials and non-PH NMA methods better reflected the relative treatment effects over time. The most flexible models (fractional polynomials and restricted cubic splines) fit better to the data than the other approaches. Estimated hazard ratios obtained with different non-PH NMA methods were similar at 5 years of follow-up but differed thereafter in the extrapolations. Although there was no strong evidence of PH violation for overall survival, non-PH NMA methods captured this uncertainty in the relative treatment effects over time. When the PH assumption is questionable in a subset of the randomized controlled trials, we recommend assessing alternative non-PH NMA methods to estimate relative treatment effects for time-to-event outcomes. We propose a transparent and explicit stepwise model selection process considering model fit, external constraints, and clinical validity. Given inherent uncertainty, sensitivity analyses are suggested.

Identifiants

pubmed: 36503035
pii: S1098-3015(22)04749-0
doi: 10.1016/j.jval.2022.11.017
pii:
doi:

Types de publication

Meta-Analysis Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

465-476

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Shannon Cope (S)

Evidence Synthesis and Decision Modeling, PRECISIONheor, Vancouver, BC, Canada. Electronic address: shannon.cope@precisionvh.com.

Keith Chan (K)

Evidence Synthesis and Decision Modeling, PRECISIONheor, Vancouver, BC, Canada.

Harlan Campbell (H)

Evidence Synthesis and Decision Modeling, PRECISIONheor, Vancouver, BC, Canada.

Jenny Chen (J)

Evidence Synthesis and Decision Modeling, PRECISIONheor, Vancouver, BC, Canada.

John Borrill (J)

Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, England, UK.

Jessica R May (JR)

Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, England, UK.

William Malcolm (W)

Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, England, UK.

Sebastien Branchoux (S)

Health Economics and Outcomes Research, Bristol Myers Squibb, Rueil-Malmaison, France.

Katrin Kupas (K)

Global Biometric Sciences, Bristol Myers Squibb, Boudry, Switzerland.

Jeroen P Jansen (JP)

Evidence Synthesis and Decision Modeling, PRECISIONheor, Vancouver, BC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH